Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: May 2010
-
The U.S. Patent and Trademark Office has announced the agenda for the next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting to be held on June 1, 2010. The proposed agenda is as follows: Morning Session • Greetings and Overview (10:00 – 10:15 am EDT): George Elliott and Remy Yucel, Directors, Technology Center 1600 • Reexam Best Practice…
-
The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled: "The Gene Uncertainty: What to Do After Myriad" on Tuesday, May 25, 2010 beginning at 2:00 PM (EST). The IPO webinar will present a panel of experts in biotech patent prosecution and litigation that will examine options for companies having gene patents or…
-
C5 (UK) will be holding its 9th Annual International Maximising Pharmaceutical Patent Life Cycles conference on June 23-24, 2010 in London, England. The conference will provide insights on: • How to profit from the latest regulatory protections available to extend patent lifecycles;• How to adjust patent strategy to developments in key pharma patent cases in…
-
By James DeGiulio — Medicis Settles Solodyn Infringement Case with Ranbaxy Medicis Pharmaceutical Corp. has reached consent and licensing agreements with Ranbaxy Laboratories Inc., thus settling patent infringement claims against Ranbaxy over Medicis' oral acne drug Solodyn. Medicis brought suit in May 2009 after receiving a Paragraph IV letter from Ranbaxy Inc. asserting that…
-
On April 28, the Court of Appeals for the Federal Circuit granted the petition for rehearing en banc submitted by Plaintiffs-Appellants Abbott Diabetes Care, Inc. (formerly Therasense, Inc.) and Abbott Laboratories in Therasense, Inc. v. Becton, Dickinson & Co. (see "Federal Circuit Grants En Banc Review in Therasense v. Becton Dickinson"). In response to requests…
-
By Andrew Williams — Last week, in Scantibodies Laboratory, Inc. v. Immutopics, Inc., the Federal Circuit affirmed a claim construction decision and corresponding summary judgment of non-infringement rendered by the U.S. District Court for the Central District of California. The patent at issue was U.S. Patent No. 6,689,566 ("the '566 patent"), "Methods, Kits, and…
-
By Kevin E. Noonan — Steve Burrill, President and CEO of Burrill & Co. took the stage at BIO 2010 in Chicago last week, and once again provided in 90 minutes his impressions and opinions on the state of the biotechnology industry. Although decidedly more upbeat than last year, Mr. Burrill's talk, entitled "Adapting…
-
By Donald Zuhn — Secretary of Commerce Writes in Support of S. 515 On April 20, Secretary of Commerce Gary Locke (at right) wrote to Senate Judiciary Committee Chairman Patrick Leahy (D-VT) and Ranking Member Sen. Jeff Sessions (R-AL), indicating that the Obama Administration strongly supported their efforts to reform U.S. patent law and…
-
By James DeGiulio — Celgene and Novartis Reach Settlement with Barr Laboratories in Ritalin ANDA Suit Celgene Corp. and Novartis AG have reached a settlement with Barr Laboratories Inc. over Barr's attempt to market a generic version of the ADHD drug Ritalin. Celgene and Novartis brought suit claiming infringement of Celgene's U.S. Patent Nos.…
-
By Nate Chongsiriwatana — Hana Biosciences, Inc. recently announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Application No. 11/886,803, entitled "Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy" (U.S. Patent Application Publication No. 2009/0209652 A1). Skin rash is a painful…
Patent Docs 